On January 16, 2019, Aptinyx announced that its drug, NYX-2925, did not achieve statistically significant separation from the placebo on a primary end point in its phase 2 trial. On this news, shares of Aptinyx fell $11.85, or 67%, to close at $5.98. The stock has yet to recover and currently trades at around $3.50, a 78% decline from its IPO price.
Robbins LLP is Investigating Allegations that PicS N.V. (PICS) Misled Investors in Connection with its IPO Robbins LLP informs stockholders that a class action was filed
Robbins LLP is Investigating Allegations that Grail, Inc. (GRAL) Misled Investors Concerning NHS-Galleri’s Potential to Achieve statistically significant reduction in Stage III-IV cancers Robbins LLP informs
Robbins LLP is Investigating Allegations that GeneDx Holdings Corp. (WGS) Misled Investors Regarding the Positive Impact of the Fabric Genomics Acquisition on the Company
Robbins LLP is Investigating Allegations that the Officers and Directors of PicS N.V. (previously PicPay Holdings) (PICS) on Behalf of Shareholders Shareholder rights law firm
Robbins LLP is Investigating Allegations that Sportradar Group AG (SRAD) Intentionally Worked with Black-Market Gambling Operators as a Business Strategy Robbins LLP informs stockholders that
Robbins LLP is Investigating Allegations that Badger Meter, Inc. (BMI) Concealed Weakening Demand and Deteriorating Near-Term Order Trends Robbins LLP informs stockholders that a class
Attorney Advertising. Past results do not guarantee a similar outcome.
5060 Shoreham Pl., Ste. 300 San Diego, CA 92122
Disclaimer | Site Map | Privacy Policy
© 2026 – Robbins LLP
Protect yourStock Watch members receive free investment monitoring and notifications.
Protect yourStock Watch members receive free investment monitoring and notifications.
